Complete Announced during: Premarket · announced Mon 9:10a ET (premarket); before = Fri close; first trade Mon 9:12a ET; time = SEC 8-K acceptance
Veradermics (NYSE: MANE) reported topline results from a Phase 2/3 trial of VDPHL01 in male pattern hair loss on April 27, 2026. The company said the trial met its primary endpoint (p<0.0001). ClinicalTrials.gov lists 480 planned participants (NCT06724614).
Trial details
- Drug
- VDPHL01Type Drug Route oral
- Treats
- Studied as a treatment for male pattern hair loss (registry condition: Androgenetic Alopecia, AGA, Male Pattern Baldness).Conditions Androgenetic Alopecia, AGA, Male Pattern Baldness
- Patients
- 480 patients (anticipated enrollment)4 arms · 44 sites in 1 country
- Phase
- Phase 2/3
- Design
- Randomized, quadruple-blind, placebo-controlled, parallel-group
- Primary endpoint
- Changes in non-vellus Target Area Hair Counts (TAHC) (Month 6) Subjects Evaluation of Treatment Benefit (Month 6)
- Result
- Met endpointIn the study, VDPHL01 achieved superior hair growth compared with placebo (p<0.0001) on the co-primary endpoints of non-vellus Target Area Hair Count (TAHC) and patient reported outcome (PRO) benefit of ‘improved’ or ‘much improved’ on the Androgenetic Alopecia Impact Rating Scale (AAIRS) at Month 6.p-value p<0.0001Figures as reported by the sponsor or registry; not calculated by DrugTrials.org.
- Safety
- The trial met all primary and all key secondary endpoints with statistical significance, demonstrating a potentially differentiated clinical profile defined by rapid onset of activity, consistent response across patients, and robust increases in hair count while being generally well tolerated…
- Sponsor
- Veradermics NYSE: MANE
- Dates
- Study start Nov 6, 2024Primary completion Feb 2026 (anticipated)Announced Apr 27, 2026, 9:10 AM ET (SEC 8-K filing time)
- Trial ID
- NCT06724614 ClinicalTrials.gov
About this trial
This randomized, quadruple-blind, placebo-controlled, parallel-group Phase 2/3 trial (NCT06724614) tested VDPHL01 in Androgenetic Alopecia, AGA and Male Pattern Baldness. Studied as a treatment for male pattern hair loss (registry condition: Androgenetic Alopecia, AGA, Male Pattern Baldness). It planned to enroll 480 patients across 4 arms at 44 sites in 1 country. The primary endpoint was Changes in non-vellus Target Area Hair Counts (TAHC) (Month 6) Subjects Evaluation of Treatment Benefit (Month 6). Veradermics reported that the trial met its primary endpoint (p-value: p<0.0001). The study started on Nov 6, 2024 and is expected to reach primary completion in Feb 2026.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
- ClinicalTrials.gov record: NCT06724614
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.